Now Reading: CDSCO finds one spurious, 220 NSQ drug samples in August surveillance
-
01
CDSCO finds one spurious, 220 NSQ drug samples in August surveillance
The Central Drugs Standard Control Organisation (CDSCO) has identified one spurious and 220 not of standard quality (NSQ) drug samples from its August surveillance exercise, according to its NSQ and Spurious Drug…
The Central Drugs Standard Control Organisation (CDSCO) has identified one spurious and 220 not of standard quality (NSQ) drug samples from its August surveillance exercise, according to its NSQ and Spurious Drug Alert issued on Tuesday. Of the NSQ samples, 29 were tested by central labs and 191 by state drug testing labs. NSQ drugs fail to meet quality standards on parameters like labelling, dissolution, weight uniformity, or sterility.
The spurious sample was found in the National Capital Territory of Delhi and was allegedly manufactured by unauthorised makers using a brand name owned by another firm. CDSCO said the matter is under investigation and action will be taken under the Drugs and Cosmetics Act. The regulator added that the finding is specific to the tested batch and does not indicate concerns about other products in the market.
Indian Opinion Analysis
The CDSCO tests thousands of drug samples annually through a joint centre-state mechanism, with NSQ rates typically hovering around 1.5% of all sampled drugs, as stated by the drugs controller general. This monthly alert system is the main tool for flagging defective batches before they reach more patients. The August tally of 220 NSQ samples, while not unusually high, underscores the persistent quality challenge in India's Rs 3 lakh crore pharmaceutical market. The next step for the spurious Delhi case will be a criminal investigation under the Drugs and Cosmetics Act, which can lead to licence cancellation and prosecution of the unauthorised manufacturer.
Source: hindustantimes.com
This brief was synthesised by AI from the source linked above.
